# IBI397 or Combination Therapies in Patients With Advanced Malignancies

> **NCT05245916** · PHASE1 · WITHDRAWN · sponsor: **Innovent Biologics (Suzhou) Co. Ltd.**

## Conditions studied

- Advanced Malignancies

## Interventions

- **DRUG:** IBI397
- **DRUG:** IBI397+Sintilimab
- **DRUG:** IBI397+Rituximab

## Key facts

- **NCT ID:** NCT05245916
- **Lead sponsor:** Innovent Biologics (Suzhou) Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-04-14
- **Primary completion:** 2023-08-24
- **Final completion:** 2023-08-24
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to the company's development strategy adjustment
- **Last updated:** 2023-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05245916

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05245916, "IBI397 or Combination Therapies in Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05245916. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*